Gynex Pharmaceuticals Inc. said it has begun shipments ofDelatestryl (testosterone enanthate), its first approved drug toprovide the company with a regular source of revenue.
Gynex (NASDAQ:GYNX) received rights to the injectabletestosterone product from Bristol-Myers Squibb in March. Thedrug is used to treat patients with testosterone deficiency, acondition associated with impotence, decreased libido,insufficient muscle development and bone loss. Approximately400,000 American men suffer from this condition, Gynex said.Squibb continues to market the drug for Gynex.
The Vernon Hills, Ill., company continues limited distribution ofOxandran, for delayed growth and puberty, through an FDAtreatment investigational new drug approval.
(c) 1997 American Health Consultants. All rights reserved.